Opinion|Videos|September 28, 2026
Choosing Between Regimens, Future Directions, and Key Takeaways
In the closing discussion, the faculty address how they choose between the available chemoimmunotherapy regimens and where the field is heading.
Advertisement
Episodes in this series
In the closing discussion, the faculty address how they choose between the available chemoimmunotherapy regimens and where the field is heading. The segment closes with the key takeaways, including reviewing the takeaways from the TOPAZ-1 study data, the consistency of independent real-world datasets, and the survival signal reported in meta-analysis.
Advertisement
Related to this article
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Reading a Changed Eye Examination and Impact on Therapy
3
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
4
ASH Issues New Myelofibrosis Guidelines With 10 Management Recommendations
5